Related references
Note: Only part of the references are listed.Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
Riccardo Danielli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
Sofie Wilgenhof et al.
CANCER INVESTIGATION (2012)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wenshi Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Advances in systemic treatment of melanoma
A. M. M. Eggermont
ANNALS OF ONCOLOGY (2010)
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer
Xin An et al.
BIOMARKERS (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effector Functions of Donor-Reactive CD8 Memory T Cells Are Dependent on ICOS Induced During Division in Cardiac Grafts
A. D. Schenk et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer
Khaled M. Sarraf et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2009)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Cutaneous melanoma: available therapy for metastatic disease
Ahmad A. Tarhini et al.
DERMATOLOGIC THERAPY (2006)
Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer
SR Walsh et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Share Paper
